The efficacy of unrelated transplantation for patients with ALL who lack an HLA-matched sibling remains unclear. We performed a decision analysis to determine the efficacy of myeloablative transplantation from a genetically HLA-A, -B, -DRB1 allele-matched unrelated donor for patients with Ph chromosome-negative ALL aged 21-54 years. The transition probabilities were estimated from the Japan Adult Leukemia Study Group studies (ALL93; n ¼ 80, ALL97; n ¼ 82), and the Japan Marrow Donor Program database (transplantation in first CR (CR1): n ¼ 177). The primary outcome measure was the 10-year survival probability with or without quality of life (QOL) adjustment. Subgroup analyses were performed according to risk stratification based on the WBC count and cytogenetics, and according to age stratification. In all patients, unrelated transplantation in CR1 was shown to be superior in analyses both with and without QOL adjustment (40.8 vs 28.4% and 43.9 vs 29.0%, respectively). A similar tendency was observed in all subgroups. The decision model was sensitive to the probability of leukemia-free survival following chemotherapy and the probability of survival after transplantation in standard-risk and higher-aged patients. Unrelated transplantation in CR1 improves the long-term survival probability in patients who lack an HLA-matched sibling. However, recent improvements in treatment strategies may change this result.
INTRODUCTION
The outcome of chemotherapy for Ph chromosome (Ph)-negative ALL in adult patients is inferior to that in children. Although about 90% of patients achieve CR, most of them eventually relapse, and leukemia-free survival is only 30-40%. 1 Therefore, allogeneic hematopoietic SCT (HSCT) in first CR (CR1) has been investigated to decrease the relapse rate. The efficacy of this approach has been evaluated through clinical studies using genetic randomization, in which patients with a HLA-matched sibling donor are allocated to the allogeneic HSCT arm, and those without a donor are placed in the chemotherapy or autologous HSCT arm. [2] [3] [4] [5] [6] [7] [8] [9] [10] These studies, as well as a meta-analysis of seven similar studies, confirmed that the donor group had a superior outcome compared with the no-donor group, and that autologous HSCT was not superior to chemotherapy in patients with adult ALL in CR1. 11 However, the efficacy of unrelated HSCT in patients with ALL in CR1, who lack an HLA-matched sibling, is still unclear.
Although retrospective studies have reported a similar outcome for related and unrelated HSCT for ALL, a major problem was that the duration between the achievement of remission and HSCT was considered to be longer in unrelated HSCT due to the coordination process. 12, 13 Therefore, patients who relapsed early after achieving remission might have been excluded in the unrelated HSCT group. On the other hand, it is practically difficult to perform a prospective clinical trial, in which patients with ALL in CR1, who lack an HLA-matched sibling but who have an HLAmatched unrelated donor, are randomly assigned to receive unrelated HSCT or chemotherapy alone.
A decision analysis is a statistical technique that aids the clinical decision making process under conditions of uncertainty. We previously demonstrated through a decision analysis that allogeneic HSCT is superior to chemotherapy alone in CR1 for adult patients with Ph-negative ALL who have an HLA-matched sibling, even after adjusting for quality of life (QOL). 14 In the 1 present study, we performed a decision analysis to evaluate the efficacy of unrelated myeloablative HSCT for adult patients with Ph-negative ALL in CR1 who lack an HLA-matched sibling. We used a decision tree based on the results of prospective studies by the Japan Adult Leukemia Study Group (JALSG) (ALL93 3 and ALL97 15 ), in which conventional-intensity regimens were used, the database of the Japan Marrow Donor Program (JMDP), 16 and the literature. Patients with Ph-positive ALL were not included in our analysis, because the outcome of treatment in these patients has improved dramatically as tyrosine kinase inhibitors became available. 17 In addition, patients aged less than 21 years were excluded from this analysis because the outcome of treatment in these patients has also improved greatly using intensified chemotherapy based on a pediatric regimen. 18 
MATERIALS AND METHODS

Model structure
We constructed a decision tree (Figure 1 ) to identify the optimal treatment strategy for adult patients with Ph-negative ALL in CR1, who lack an HLAmatched sibling, but who have an HLA-matched unrelated donor. At a decision node, we can decide to either proceed to unrelated HSCT or continue chemotherapy in CR1. Each decision is followed by chance nodes, which have possible outcomes with a transition probability (TP), and every branch finally ends with terminal nodes, which have utilities according to different health states. The sum of the products of the transition probabilities and utilities of all branches following each chance node become the expected value of each chance node, and the expected value of each decision is calculated as the sum of the expected values in all of the chance nodes following each decision. The following analyses were performed using TreeAge Pro 2009 software (Williamstown, MA, USA). This study was approved by the Institutional Review Boards of JMDP and Jichi Medical University.
Data sources
Outcomes after continuing chemotherapy in CR1 were estimated from JASLG studies (ALL93 3 and ALL 97 15 ). Patients with Ph-negative ALL aged 21-54 years were included, and those who never achieved remission with chemotherapy were excluded. The data from 80 patients in ALL93 and 82 patients from ALL97 were analyzed separately and then combined by weighting the number of patients. Outcomes after unrelated HSCT in various disease statuses were estimated from the database of JMDP.
Patients with Ph-negative ALL aged 21-54 years who underwent a first myeloablative allogeneic HSCT from a genetically HLA-A, -B, -DRB1 allelematched unrelated donor between 1993 and 2008 were included. Of these, 177, 45 and 62 patients were in first remission, second remission and non-remission, respectively, at unrelated HSCT. All patients received BM graft.
The characteristics of the patients included in this study are summarized in Table 1 . There was no significant difference in baseline characteristics among the JALSG studies and the JMDP data. To determine the following transition probabilities, OS and leukemia-free survival with a 95% confidence interval (CI) were calculated using the Kaplan-Meier method, whereas the cumulative incidences of non-relapse mortality and relapse with 95% CI were calculated using Gray's method, 19 where the other event was considered a competing risk. Probabilities that we could not estimate from these data were estimated from the literature.
Transition probabilities and utilities
Transition probabilities of the entire population were determined as summarized in Table 2 . Each TP has a baseline value and a plausible range. Baseline decision analyses were performed based on the baseline value.
Patients may have been precluded from the undergoing unrelated HSCT due to early relapse or comorbidities even if they decided to undergo HSCT, and therefore the TP of actually undergoing unrelated HSCT in CR1 after the decision branch to undergo HSCT was determined as follows. First, the median duration between the achievement of CR1 and HSCT without relapse was calculated as 270 days based on the JMDP data. Next, leukemia-free survival rates at 270 days after achieving CR1 were calculated using the data for all patients who achieved remission in the JALSG studies, and the combined leukemia-free survival was 0.70 (95% CI: 0.64-0.77). We considered this to be the TP for actually receiving HSCT in CR1, and assigned a baseline value of 0.70 and 95% CI to the plausible range. The TP of undergoing unrelated HSCT in second remission (CR2) after the patient had a relapse following a decision to continue chemotherapy could not be calculated from our data. We assigned a plausible range of 0.5-0.70; the former value was the only available rate in a large study, 20 and the latter was the TP calculated above. The median of this range was taken as the baseline value. Probabilities regarding the actual rate of receiving HSCT in other disease statuses could not be obtained, even in the literature. Therefore, a baseline value of 0.5 was assigned with a wide plausible range of 0.3-0.7. The TP values for 'Alive at 10 years' following HSCT in various disease statuses were determined based on the JMDP data. We assigned 95% CI to the plausible ranges. Recently, results of HSCT in more specific disease statuses, such as HSCT following an early or late relapse after chemotherapy 21 and HSCT following Figure 1 . Decision tree used in this study. Decision analysis was performed based on this decision tree. A square indicates a decision node and open circles indicate chance nodes. In analyses with a QOL adjustment, 'Alive' after transplantation was followed by two branches with or without active chronic GVHD (dotted arrow). *Unrelated hematopoietic SCT (uHSCT) was not performed due to early relapse, death and so on. ALL, acute lymphoblastic leukemia; CR, complete remission; NRM ¼ non-relapse mortality. a relapse after first HSCT, 22 have been reported, but sufficient data for this decision analysis were not provided in these reports.
The transition probabilities for 'Alive without relapse at 10 years' and non-relapse mortality following chemotherapy in CR1 were determined based on the JALSG studies, and the TP of relapse following chemotherapy was determined by subtracting the sum of these TPs from one. The TP of achieving CR2 after relapse in patients who decided to continue chemotherapy in CR1 was estimated to have a baseline value of 0.4 with a plausible range of 0.3-0.5 based on the literature. 10, 20, 23 Utilities were calculated based on a 10-year survival probability, which was the primary outcome measure, with or without adjusting for QOL. The survival curve nearly reaches a plateau after 5 years, and therefore 'Alive at 10 years' reflects 'Cure of leukemia', which is the primary goal of HSCT. In an analysis without an adjustment for QOL, we considered only two kinds of health states, 'Alive at 10 years' and 'Dead', and assigned utility values of 100 to the former and 0 to the latter. On the other hand, in an analysis with an adjustment for QOL, 'Alive after chemotherapy without relapse at 10 years', 'Alive with active GVHD at 10 years' and 'Alive without active GVHD at 10 years' were considered as different health states. The proportion of patients with active GVHD among those who were alive at 10 years was determined based on the literature. [24] [25] [26] We assigned a value of 100 to the utility for being alive without relapse at 10 years after chemotherapy alone, and a value of 0 to the utility for being dead in all situations. We assigned a fixed value of 98 to the utility for being alive without active GVHD at 10 years following HSCT because a part of patients had suffered from complications other than active GVHD, such as cataract. 27 Moreover, we assigned a value of 70 with a wide plausible range of 0-98 to the utility for being alive with active GVHD at 10 years. These utilities were determined based on the opinions of 10 doctors who were familiar with HSCT and the literature. 28, 29 Subgroup analyses were also performed according to risk stratification based on the WBC count and cytogenetics, and according to age stratification with a cutoff of 35 years. This cutoff value is based on the age used in the Medical Research Council/Eastern Cooperative Oncology Group trial for risk stratification. 9 Patients with a high WBC count (more than 30 Â 10 9 /L for B lineage and more than 100 Â 10 9 /L for T lineage) and/or with t(4;11) or complex karyotype (5 or more chromosomal abnormalities) were classified as high-risk, and all other patients were classified as standard-risk. It was difficult to perform other subgroup analyses regarding the possible prognostic factors like phenotypes, due to the limited number of patients involved. All transition probabilities, based on the JALSG studies and the JMDP data, were recalculated using the data for patients in each subgroup (Table 2) .
Sensitivity analyses
To evaluate the robustness of the decision model, we performed one-way sensitivity analyses for all transition probabilities, in which the decision tree was recalculated by varying each TP value in its plausible range, and confirmed whether or not the decision of the baseline analyses changed. In analyses with an adjustment for QOL, the utility for being alive with The same baseline value and plausible range were used as the rate of active GVHD at 10 years following HSCT in various disease statuses, but one-way sensitivity analyses were performed separately for each status.
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We also performed a probabilistic sensitivity analysis using a Monte Carlo simulation 30 , in which the uncertainties of all transition probabilities were considered simultaneously. The distribution of the random variables for each TP was determined to follow a normal distribution, with 95% of the random variables included in the plausible range. One thousand simulations were performed based on the decision tree, and the mean and s.d. of the expected value for each decision were calculated.
RESULTS
Baseline analysis
The baseline analysis in the overall population without adjusting for QOL revealed an expected 10-year survival of 43.9% for the decision to perform unrelated HSCT in CR1, which was better than the value (29.0%) for the decision to continue chemotherapy. The decision to perform unrelated HSCT was superior even after adjusting for QOL (40.8% for HSCT vs 28.4% for chemotherapy, Table 3 ).
Sensitivity analysis First, we performed one-way sensitivity analyses for all transition probabilities in the decision model without adjusting for QOL. A better expected survival for the decision to perform HSCT was consistently demonstrated in all transition probabilities within the plausible ranges. In the probabilistic sensitivity analysis, the mean value and s.d. of the expected survival probability for HSCT were 44.0 and 3.5% (Figure 2a) , and those for chemotherapy were 29.1 and 3.9% (Figure 2b) , respectively.
Next, we performed one-way sensitivity analyses for all transition probabilities and for the utility for being alive with active GVHD at 10 years in the decision model adjusted for QOL. Even in these analyses, the results of the baseline analysis were not reversed for any of the transition probabilities. In addition, a higher expected survival probability for HSCT was retained in a sensitivity analysis, in which the utility for being alive with active GVHD was changed between 0 and 98 (Figure 3a) . In the probabilistic sensitivity analysis, the mean value and s.d. of the expected survival probability for HSCT were 40.9 and 3.4% (Figure 2c) , and those for chemotherapy were 28.4 and 3.9% (Figure 2d ), respectively. Probabilistic sensitivity analysis (PSA) using a Monte Carlo simulation. We performed a PSA using a Monte Carlo simulation. In the analysis without a QOL adjustment, the mean value (MV) and s.d. of the expected survival probability for unrelated HSCT were 44.0 and 3.5% (a), and those for chemotherapy (CTx) were 29.1 and 3.9% (b), respectively. In the analysis with a QOL adjustment, the MV and s.d. of the expected survival probability for HSCT were 40.9 and 3.4% (c), and those for CTx were 28.4 and 3.9% (d), respectively.
Subgroup analyses
In subgroup analyses both with and without adjusting for QOL, a better expected survival probability for HSCT was consistently observed in all of the subgroups (Table 3) . We also performed one-way sensitivity analyses in all of the subgroups. In high-risk and lower-aged patients, the results of baseline analyses were not affected when each TP value was varied within its plausible range in the decision models both with and without adjusting for QOL. In standard-risk patients, the results reversed in favor of chemotherapy if the probability of leukemia-free survival at 10 years without relapse following chemotherapy was higher than 0.35 (Figure 3b) or the probability of OS at 10 years following HSCT in CR1 was lower than 0.42 (Figure 3c ) in the decision model without adjusting for QOL. In the decision model with adjusting for QOL, the results reversed in favor of chemotherapy if the probability of leukemia-free survival at 10 years without relapse following chemotherapy was higher than 0.32 (Figure 3f ) or the probability of OS at 10 years following HSCT in CR1 was lower than 0.45 (Figure 3g) . In older patients, the decision models both with and without adjusting for QOL were also sensitive to both the probability of leukemia-free survival at 10 years without relapse following chemotherapy and the probability of OS at 10 years following HSCT in CR1 (Figures 3d, e, h and i). We also performed one-way sensitivity analyses for a utility for being alive with active GVHD within the range of 0-98. A higher expected survival probability for HSCT was retained in all of the subgroups.
DISCUSSION
About two-thirds of patients with adult ALL lack an HLA-matched sibling, and for these patients, allogeneic HSCT from an HLAmatched unrelated donor might be an alternative treatment. Several studies have suggested that unrelated HSCT may be effective for high-risk adult ALL patients in various disease statuses. 31, 32 In addition, two retrospective studies showed no difference between related and unrelated HSCT for adult ALL patients, including those in CR1, 12, 13 and the recent evidencebased review from the American Society for Blood and Marrow Transplantation supported this. 33, 34 However, patients who undergo unrelated HSCT in CR1 are a select population of patients who have maintained their remission status during the donor-coordination process. We performed a decision analysis to identify the optimal strategy for patients with ALL in CR1, who lack an HLA-matched sibling but who have an HLA-matched unrelated donor. We tried to exclude selection bias in patients who underwent unrelated transplantation by considering patients who did not undergo unrelated HSCT in CR1 due to early relapse or comorbidities even if they decided to undergo unrelated HSCT.
We used data from JALSG prospective studies to estimate outcomes after continuing chemotherapy. On the other hand, we used the database of JMDP to estimate outcomes after unrelated HSCT, due to the limited number of patients who underwent unrelated HSCT in the JALSG prospective studies. The outcomes after unrelated HSCT in CR1 were not significantly different among the JALSG prospective studies and the JMDP database. (OS at 10 years in patients who underwent unrelated HSCT in CR1 was 54.2, 50 and 58.2% in JALSG ALL93 study, JALSG ALL97 study, and the JMDP database, respectively (P ¼ 0.56 in log-rank test)).
In our baseline analysis both with and without adjusting for QOL, unrelated HSCT in CR1 was shown to give a superior outcome in both the overall population and in all of the subgroups. In the overall population, probabilistic sensitivity analysis using a Monte Carlo simulation also supported this result ( Figure 2) . However, in a one-way sensitivity analysis, the decision model was sensitive to the probability of leukemia-free survival following chemotherapy in CR1 in both standard-risk and older patients (Figures 3b, d, f and h ). The adaptation of highintensified chemotherapy, especially the adaptation of chemotherapy according to pediatric regimens up to young adult, has led to improved outcomes in recent trials, 1, 9, 10 but the JALSG studies in this analysis included less-intensified regimens. Therefore, this improvement in chemotherapy might change our result. In a one-way sensitivity analysis, the decision model was also sensitive to the probability of OS at 10 years following HSCT in CR1 in both standard-risk and older patients (Figures 3c, e, g  and i) . This study only included data on unrelated HSCT from a genetically HLA-A, -B, -DRB1 allele-matched donor. It has been One-way sensitivity analysis. We performed a one-way sensitivity analysis. The superiority of unrelated HSCT compared with CTx was consistently observed with a wide plausible range of the utility for being alive with active GVHD in the overall population (a). On the other hand, the models both without adjusting for QOL were sensitive to the probability of leukemia-free survival at 10 years following CTx and the probability of OS at 10 years following HSCT in CR1 in standard-risk (b, c, f, g) and older patients (d, e, h, i).
reported that the presence of an HLA allele mismatch, especially in some specific combinations, significantly affects the outcome of serologically HLA-matched unrelated HSCT. 35 Therefore, the indications for HSCT from an unrelated donor with an HLA allele mismatch should be considered with great caution, especially in standard-risk and older patients.
Recently, minimal residual disease assays are increasingly involved in the evaluation of treatment response for ALL, 36 and the prevalence of minimal residual disease after the induction therapy or early consolidation therapy has been demonstrated as an important prognostic factor. In the current study, we considered only hematological response, and minimal residual disease status was not included in risk stratification. Minimal residual disease status should be taken into account in the future analysis.
In this study, the median duration from achieving CR1 to unrelated HSCT without relapse was 270 days, which precluded HSCT in CR1 in 30% of patients after a decision to perform HSCT (mainly due to early relapse). This duration was 4 months longer than the duration from achieving CR1 to related HSCT without relapse in our previous study, as the coordination process for an unrelated donor through JMDP requires a longer duration. A meta-regression analysis by Yanada et al. 11 showed that the proportion of patients who actually underwent allogeneic HSCT among patients with a donor was positively correlated with survival. The coordination process for a JMDP donor is currently getting shorter, and, as a consequence, the efficacy of unrelated HSCT in CR1 may increase.
The low incidence of severe GVHD has been demonstrated in Japanese patients, 37, 38 and this might have influenced the superior outcome of unrelated HSCT in CR1 in our analysis. Therefore, caution should be paid when the current results are applied to patients of other origins.
In conclusion, to improve the probability of long-term survival, myeloablative HSCT from a genetically HLA-A, -B, -DRB1 allelematched unrelated donor in CR1 is recommended for patients, aged 21-54 years, who lack an HLA-matched sibling donor. Even when we considered QOL, the superiority of unrelated HSCT was confirmed in the overall population and in all of the subgroups. However, recent improvements in treatment strategies, like highintensified chemotherapy, may change this result.
